Analysis of the grouping effect and hospitalization cost of patients with malignant proliferative disease in a hospital under DRG payment

XIANG Guiyuan; WU Yuanlin; GAN Lanlan; CHEN Shigeng; LIU Yao

doi:10.6039/j.issn.1001-0408.2023.13.18

您当前的位置：

首页 >

文章列表页 >

Analysis of the grouping effect and hospitalization cost of patients with malignant proliferative disease in a hospital under DRG payment

更新时间：2023-08-15

- Analysis of the grouping effect and hospitalization cost of patients with malignant proliferative disease in a hospital under DRG payment
- ZHONGGUO YAOFANG Vol. 34, Issue 13, Pages: 1637-1641(2023)
- 作者机构：
  
  1.陆军特色医学中心药剂科，重庆　400042
  2.陆军特色医学中心医保办，重庆　400042
- 作者简介：
- 基金信息：
- DOI：10.6039/j.issn.1001-0408.2023.13.18
  CLC： R979.1;R956
- Published：15 July 2023，
  
  Received：30 December 2022，
  
  Revised：02 June 2023，
扫描看全文
向贵圆,伍渊麟,甘岚澜等.DRG支付下某院恶性增生性疾患分组效果与住院费用分析 ^Δ[J].中国药房,2023,34(13):1637-1641.

XIANG Guiyuan,WU Yuanlin,GAN Lanlan,et al.Analysis of the grouping effect and hospitalization cost of patients with malignant proliferative disease in a hospital under DRG payment[J].ZHONGGUO YAOFANG,2023,34(13):1637-1641.
向贵圆,伍渊麟,甘岚澜等.DRG支付下某院恶性增生性疾患分组效果与住院费用分析 ^Δ[J].中国药房,2023,34(13):1637-1641. DOI： 10.6039/j.issn.1001-0408.2023.13.18.

XIANG Guiyuan,WU Yuanlin,GAN Lanlan,et al.Analysis of the grouping effect and hospitalization cost of patients with malignant proliferative disease in a hospital under DRG payment[J].ZHONGGUO YAOFANG,2023,34(13):1637-1641. DOI： 10.6039/j.issn.1001-0408.2023.13.18.

摘要

目的

分析某医院疾病诊断相关分组（DRG）支付下恶性增生性疾患的分组效果与住院费用构成及变动情况，为医疗机构改进DRG付费相关措施、控制药品费用以及有关部门制定相关决策提供依据。

方法

收集某“三甲”综合医院2021、2022年的恶性增生性疾患住院病例信息，使用变异系数（CV）对DRG分组效能进行评价，结合结构变动度与新灰色关联分析法研究住院费用的结构变动及其与各项费用间的关联程度。

结果

恶性增生性疾患DRG病组总体变异降低系数（RIV）为79.36%，除RW21病组CV为1.09外其他病组CV均小于1；相比于2021年，2022年恶性增生性疾患的次均住院费用下降了17.80%，管理费、药品费的降幅分别为32.15%、21.30%，医疗费的增幅为17.26%；药品费的新灰色关联度降低，但医疗费的新灰色关联度升高。

结论

DRG支付下样本医院恶性增生性疾患住院费用下降，但RW21等病组的分组效能有待提升，费用结构有待优化。

Abstract

OBJECTIVE

To analyze the grouping effect and composition of hospitalization costs for cases of patients with malignant proliferative disease under the diagnosis-related group （DRG） payment system， as well as any changes， in order to provide a basis for medical institutions to improve DRG payment-related measures， control drug costs， and for relevant departments to make decisions.

METHODS

The data of patients with malignant proliferative disease cases were collected from a “Third Grade Class A” hospital in 2021 and 2022， and the variation coefficient （CV） was used to evaluate the grouping of DRG. The structural variation degree and the new grey correlation analysis were used to study the structural variation of hospitalization cost and the correlation degree between the hospitalization cost and the cost of other items.

RESULTS

The overall reduction in variance （RIV） for the DRG group of patients with malignant proliferative disease was 79.36%； the CV of other groups were all lower than one except that the RW21 group was 1.09. Compared with 2021， the hospitalization cost for patients with malignant proliferative disease in 2022 decreased by 17.80%， and the decreases in management fees and drug costs were 32.15% and 21.30%， respectively， while the per capita medical expenses increased by 17.26%. The new grey correlation degree of drug cost decreased， but that of medical expenses increased.

CONCLUSIONS

Under the DRG payment system， hospitalization costs for patients with malignant proliferative disease in the sample hospital decrease， but the grouping efficiency of RW21 and other disease groups needs improvement， and the cost structure needs optimization.

关键词

疾病诊断相关分组恶性增生性疾患分组效果住院费用

Keywords

patients with malignant proliferative diseasegrouping effecthospitalization costs

references

TULCHINSKY T H. Case studies in public health[M]. San Diego，CA，USA：Academic Press，2018：357-382.

GOLDFIELD N. The evolution of diagnosis-related groups （DRGs）：from its beginnings in case-mix and resource use theory，to its implementation for payment and now for its current utilization for quality within and outside the hospital[J]. Qual Manag Health Care，2010，19（1）：3-16.

国家医疗保障局.国家医保局召开疾病诊断相关分组（DRG）付费国家试点工作启动视频会议[EB/OL].（2019-05-24） [2022-09-28].http：//www.nhsa.gov.cn/art/2019/5/24/art_14_1334.htmlhttp://www.nhsa.gov.cn/art/2019/5/24/art_14_1334.html.

SUNG H，FERLAY J，SIEGEL R L，et al. Global cancer statistics 2020：GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin，2021，71（3）：209-249.

CAI Y E，XUE M，CHEN W Q，et al. Expenditure of ho- spital care on cancer in China，from 2011 to 2015[J]. Chin J Cancer Res，2017，29（3）：253-262.

国家医疗保障局.国家医疗保障DRG分组与付费技术规范[EB/OL].（2019-10-24） [2022-10-03].http：//www.nhsa.gov.cn/art/2019/10/24/art_104_6464.htmlhttp://www.nhsa.gov.cn/art/2019/10/24/art_104_6464.html.

张雅莉，荆媛，姚魏紫，等.基于DRG的剖宫产病例分组效果与费用结构分析[J].卫生经济研究，2020，37（7）：37-40.

雒敏，黄亚新. 2015－2019年江苏省某综合性三甲医院住院费用结构变动度分析[J].中国卫生事业管理，2022，39（4）：262-264，286.

魏安华，贡雪芃，王璐，等. 临床药师基于结构变动度对DRG超支病例用药合理性分析与研究[J]. 药物流行病学杂志，2022，31（2）：93-96.

孙芳芳. 浅议灰色关联度分析方法及其应用[J]. 科技信息，2010（17）：880-882.

马宗奎，刘明孝，胡靖琛，等. 基于新灰色关联与结构变动度的DRG付费改革对冠心病患者次均住院费用影响[J]. 中国医院管理，2022，42（8）：70-73.

东亚斌，段志善. 灰色关联度分辨系数的一种新的确定方法[J]. 西安建筑科技大学学报（自然科学版），2008，40（4）：589-592.

赵斌，陈曼莉，丁文雅. 我国病种分值结算方式的再检验：基于典型DRGs的概念框架[J]. 中国医疗保险，2018（12）：28-32.

中国政府网.74种新药进医保谈判成功率再创新高：解读2021年新版国家医保药品目录[EB/OL].（2021-12-04） [2023-05-25].http：//www.gov.cn/zhengce/2021-12/04/content_5655779.htmhttp://www.gov.cn/zhengce/2021-12/04/content_5655779.htm.

中国政府网.第五批国家组织药品集采中选结果公布：集中带量采购，减轻看病负担[EB/OL].（2021-07-14） [2023-05-25]. http：//www.gov.cn/xinwen/2021-07/14/content_5624766.htmhttp://www.gov.cn/xinwen/2021-07/14/content_5624766.htm.

中国政府网.第四批国家药品集采开标拟中选药品平均降价52%[EB/OL].（2021-02-03） [2023-05-25].http：//www.gov.cn/xinwen/2021-02/03/content_5584689.htmhttp://www.gov.cn/xinwen/2021-02/03/content_5584689.htm.

刘芳，尹龙燕，关华，等. 基于DRG分析临床路径管理对住院费用的影响[J]. 广州医药，2020，51（1）：74-77.

蒋慧群，李歆，韩峰. 国家医保谈判抗肿瘤药物在常州地区可获得性和可负担性研究[J]. 中国药物警戒，2021，18（11）：1075-1079.

孙睿，夏芷玫，梁越，等.公立医院抗肿瘤药物可获得性与可负担性研究：基于江苏省公立医院典型调查的数据分析[J].价格理论与实践，2019（5）：39-42，75.

刘跃华，向贵圆，刘昭.我国抗肿瘤靶向药物医保政策实施现状与改进建议[J].中国药物经济学，2022，17（9）：57-60，66.

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

城市地区房颤脑卒中患者住院费用分析

广州市强直性脊柱炎参保患者医疗费用的影响因素分析

Related Author

吴静静杨莉

郑庆偲夏苏建

Related Institution

No data

Address：8/F,129 Daping Main Street,Yuzhong District,Chongqing 400042,P.R.China
Technical support is provided by Beijing Founder Electronics co., LTD 渝ICP备15012710号公网安备50010302001817
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰